Details

Autor(en) / Beteiligte

• Hamilou, Zineb
• Lavaud, Pernelle
• Loriot, Yohann

Titel

Atezolizumab in urothelial bladder carcinoma

Ist Teil von

• Future oncology (London, England), 2018-02, Vol.14 (4), p.331-341

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Metastatic bladder cancer is an aggressive malignancy with a poor prognosis when presenting with advanced stage. Cisplatin-based therapy has been the mainstay of first-line treatment but therapy in second-line setting has been an unmet medical need for decades. Moreover, many patients are unable to receive cisplatin-based therapy. Recently, immune-checkpoint inhibitors transformed the management and prognosis of many malignancies and will certainly redefine the standard of care for bladder cancer. Atezolizumab, an anti-PD-L1 antibody, was the first immune-checkpoint inhibitor to be approved by the US FDA in May 2016 for patients with urothelial carcinoma. In this review, we discuss the evidence behind this promising drug.